Delivery Order SPE2DR25D2101-SPE2DR26F47FP
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 18, 2025, by the Defense Logistics Agency (DLA) for the supply of LEQVIO 284 mg/1.5 mL syringes with a ceiling value of $16,278.85. This firm fixed-price delivery order, which is scheduled for completion by July 11, 2025, is unset-aside and competitively awarded. The award represents a continuation of the company's substantial role as a critical...
- The Defense Logistics Agency awarded a $49,015.40 delivery order to AmerisourceBergen Drug Corp for LEQVIO (inclisiran) 284 mg/1.5 mL syringes on December 17, 2025, with completion targeted for January 9, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under the company's...
- On January 8, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $24,812.70 to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes. This firm fixed-price delivery order, which is not set-aside, is expected to be completed by January 30, 2026, with performance taking place at the awardee's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop...
- The U.S. government awarded a $10,987.05 firm fixed price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division, a subsidiary of AmerisourceBergen Corporation. The contract is for the delivery of LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML, with a completion date of May 8, 2024. The award was made by the Medical Supply Chain, a defense agency under the Defense Department. AmerisourceBergen, a major pharmaceutical distributor, leverages its extensive supply chain to fulfill...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a delivery order valued at $6,509.43 by the Defense Logistics Agency to supply 4561585039 LEQVIO 284 MG/1.5 ML SYRINGES in quantities of 1.5ML each. Performance will take place in Conshohocken, Pennsylvania under firm fixed pricing over a three week period concluding in mid-August. The Defense Logistics Agency utilizes numerous contracts government-wide to facilitate procurement of medical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $6,976.65, is for the delivery of LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML, a specialty pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of February 7, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML. The $4,394.82 firm fixed-price contract has a completion date of September 17, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of medical commodities, including...
- Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order against its indefinite delivery contract with the Defense Logistics Agency Troop Support Medical (DLA Troop Support Medical) to supply 4563004069 LEQVIO 284 MG/1.5 ML SYRINGES 1.5ML. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania, with an estimated completion date of December 27, 2023. The potential value of this order is...
- Amerisourcebergen Drug Corp has received a $6,509.43 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply 4562879802 LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML pharmaceutical products. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania, with all supplies delivered by December 13, 2023. No set-aside designation was applied to this award made against an existing DLA contract vehicle. Amerisourcebergen currently...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply 284 mg/1.5 mL syringes of the pharmaceutical product LEQVIO. The order, worth $10,987.05, has a completion date of February 12, 2024 and was awarded on January 22, 2024. Amerisourcebergen Drug Corp, as a prime contractor, has a history of providing pharmaceutical products and medical supplies to support DLA...
- SPE2DR25D2101Indefinite Delivery Contract
- SPE2DR25D2101-SPE2DR26F47FPDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $22,331.43 by the Defense Logistics Agency on January 12, 2026, for the supply of LEQVIO 284 mg/1.5 mL syringes. The contract, awarded on a non-set-aside, firm fixed-price basis, is scheduled for completion by February 3, 2026, with performance taking place at the company's Conshohocken facility. This delivery order represents a task order placed against AmerisourceBergen's parent company, Cencora, Inc.'s, substantial Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical, valued at up to $999,999,999.00 through December 2031. The award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier to the Defense Logistics Agency's Medical Supply Chain, supporting military healthcare systems globally. LEQVIO (inclisiran) is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular disease, demonstrating the company's capacity to deliver specialized pharmaceutical products to support federal military and veteran healthcare programs. The transaction exemplifies the company's established operational efficiency and capability to meet federal procurement requirements for essential medical commodities through open and competitive procedures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.3k | 1/11/26 |